Missed the 2019 BIO Investor Forum? Sign up for the Virtual Attendee Package and gain access to recorded video of 12 educational sessions, including panel discussions and fireside chats.
6:30 AM - 5:00 PM | Registration |
7:00 AM - 7:55 AM | Networking Breakfast |
7:20 AM - 5:30 PM | Satellite Partnering Desk |
7:30 AM - 5:30 PM | BIO One-on-One Partnering Meetings |
8:30 AM - 4:55 PM | Company Presentations |
8:30 AM - 9:40 AM | The Next Wave of Cancer Treatments: Allogenic Cell Therapies and Other Pioneers |
9:45 AM - 10:40 AM | Private Investors' Incubators for University-Sourced Ideas |
10:45 AM - 11:40 AM | Gene Therapies: Pipelines Into A New Era for Patients |
12:00 PM - 12:30 PM | Networking Lunch |
12:30 PM - 12:45 PM | Plenary - BIO's President and CEO Jim Greenwood presents a Policy Update |
12:45 PM - 1:40 PM | Plenary - Public Policy Outlook on Biotech Investment from China |
2:00 PM - 2:55 PM | Fireside Chat: Lon Cardon, PhD, Chief Scientific Strategy Officer, BioMarin |
3:00 PM - 3:55 PM | Recruiting Talent to Meet Corporate Board Requirements and Representation Goals |
4:00 PM - 4:55 PM | View from the Board: Making an Acquisition Offer |
5:30 PM - 6:30 PM | Opening Reception |
7:00 AM - 7:55 AM | Networking Breakfast |
7:00 AM - 4:30 PM | Registration |
7:00 AM - 5:00 PM | BIO One-on-One Partnering Meetings |
8:30 AM - 4:55 PM | Company Presentations |
8:30 PM - 9:40 AM | Progress in CNS Drug Development Outside Dementia |
9:45 AM - 10:40 AM | Advice on Pitching to Family Offices, Ventures Philanthropies, and Other Non-VC Funding Sources |
10:45 AM - 11:40 AM | Molecular Diagnostics: Drivers of New Investor Interest and Reimbursement Success |
12:00 PM - 1:25 PM | Fireside Chat: Wende Hutton, General Partner, Canaan |
1:45 PM - 2:40 PM | Separating Artificial Intelligence Hype from Real Utility in Drug Development |
2:45 PM - 3:55 PM | Best Practices in Biopharma Alliances with Digital Therapeutics Partners |
4:00 PM - 4:55 PM | Market Outlook - Taking the Temperature of the IPO Market in an Era of Large Pharma M&A |